Cybin files two new patent applications in support of its proprietary psychedelic compounds.
Cybin files two new patent applications in support of its proprietary psychedelic compounds.
Patent protection is of critical importance to the emerging psychedelic drug industry. With two types of drug patents and much additional patentable IP, there is much for investors to learn.
Optimi Health announces it has filed a Final Shelf Prospectus.
Mydecine signs a 5-year research agreement with Johns Hopkins University, with an initial focus on smoking cessation.
MindMed announces joining a research consortium, the Patient-Reported Outcome Consortium, to assist in its mission to advance medical innovation.
Cybin announces the filing of a non-provisional patent application, the company's 14th patent application.
Field Trip Health Ltd., a leader in the development and delivery of psychedelic therapies, reported its fiscal first quarter 2022 results for the three months ended June 30, 2021.
MindMed reports a Q2 2021 loss of $36 million. Current cash on hand of $157 million.
ATAI's newest research partner, Revixia Life Sciences, is seeking to treat depression and substance abuse with Salvinorin A, a lesser-known psychedelic used by indigenous peoples.
Wesana Health announces the commencement of pre-clinical psychedelics research for Traumatic Brain Injury.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now